Insider Selling: Personalis (NASDAQ:PSNL) CEO Sells $120,984.98 in Stock

Posted by Geri Gentry on Sep 25th, 2026

Personalis, Inc. (NASDAQ:PSNL – Get Free Report) CEO Christopher Hall sold 7,459 shares of the company’s stock in a transaction on Friday, September 18th. The shares were sold at an average price of $16.22, for a total value of $120,984.98. Following the completion of the sale, the chief executive officer owned 228,527 shares in the company, valued at $3,706,707.94. This trade represents a 3.16% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Personalis Price Performance

Personalis stock opened at $16.57 on Friday. The firm has a market capitalization of $1.74 billion, a P/E ratio of -15.20 and a beta of 2.31. The stock has a fifty day moving average price of $15.12 and a two-hundred day moving average price of $11.06. Personalis, Inc. has a 52-week low of $4.95 and a 52-week high of $18.89.

Personalis (NASDAQ:PSNL – Get Free Report) last posted its earnings results on Tuesday, August 4th. The company reported ($0.30) earnings per share for the quarter, missing the consensus estimate of ($0.26) by ($0.04). The firm had revenue of $22.36 million during the quarter, compared to the consensus estimate of $16.69 million. Personalis had a negative return on equity of 46.47% and a negative net margin of 153.84%. On average, equities research analysts predict that Personalis, Inc. will post -1.07 EPS for the current fiscal year.

Institutional Investors Weigh In On Personalis

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Caitong International Asset Management Co. Ltd boosted its holdings in Personalis by 76.1% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 3,423 shares of the company’s stock valued at $27,000 after acquiring an additional 1,479 shares during the last quarter. Quantbot Technologies LP bought a new stake in Personalis during the 2nd quarter worth about $69,000. Jasper Ridge Partners L.P. acquired a new position in Personalis during the 2nd quarter valued at about $193,000. AXQ Capital LP bought a new position in shares of Personalis in the 4th quarter valued at about $119,000. Finally, ADAR1 Capital Management LLC bought a new position in shares of Personalis in the 2nd quarter valued at about $201,000. Institutional investors own 61.91% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on PSNL. Needham & Company LLC downgraded Personalis from a “buy” rating to a “hold” rating in a report on Monday, July 20th. BTIG Research lifted their price objective on Personalis from $11.00 to $16.25 and gave the company a “buy” rating in a research report on Monday, July 20th. Morgan Stanley boosted their price objective on Personalis from $9.00 to $13.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 9th. Wall Street Zen cut Personalis from a “hold” rating to a “sell” rating in a report on Saturday, June 13th. Finally, Lake Street Capital cut Personalis from a “buy” rating to a “hold” rating and set a $16.25 price target for the company. in a report on Monday, July 20th. Four analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $14.54.

Get Our Latest Stock Analysis on Personalis

About Personalis

(Get Free Report)

Personalis, Inc is a genomics company focused on precision oncology and advanced molecular testing. The company develops and commercializes genomic products designed to help identify, monitor and characterize cancer, supporting more informed treatment decisions and the development of targeted therapies.

Its offerings include tissue- and blood-based tumor profiling, liquid biopsy testing and immune profiling. Personalis’ technologies are designed to detect and track tumor-derived signals, evaluate genomic alterations and provide insights into the interaction between cancer and the immune system.